WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million

ABVC raises $3.39 million via convertible notes to fund operations and settle claims.

What the company is saying

ABVC BioPharma, Inc. has closed a private placement of original issue discount senior convertible promissory notes, raising approximately $3.39 million in gross proceeds before fees and expenses. The company frames this as a strategic financing move, emphasizing that the 17.5% OID Notes, totaling $4,106,060 in principal, mature on June 30, 2027, and are convertible after eight months at 85% of the average of three recent VWAPs. ABVC highlights that proceeds will be used for general working capital, subsidiary funding, and a $625,000 settlement payment to Lind Global Fund II LP, which is positioned as resolving outstanding claims and enabling further business development. The announcement underscores the company's multi-platform approach, naming AiBtl BioPharma Inc., OncoX BioPharma, ForSeeCon Eye, and BioKey (Cayman), Inc. as key subsidiaries targeting CNS, oncology, ophthalmic, and contract pharma markets. The tone is optimistic, linking the financing to broader ambitions for licensing, milestone payments, royalties, and equity value, but operational specifics are not detailed. WallachBeth Capital, Inc. is credited as placement agent, with legal counsel roles named for both sides.

What the data suggests

The company has secured $3.39 million in gross proceeds through the issuance of 17.5% original issue discount senior convertible notes, with a total principal amount of $4,106,060 and a maturity date of June 30, 2027. The notes are convertible after eight months at a 15% discount to the average of three recent trading-day VWAPs, introducing potential dilution depending on future share price performance. Of the proceeds, $625,000 is earmarked for a settlement payment to Lind Global Fund II LP, addressing outstanding payment claims. The remainder is allocated to general working capital and subsidiary funding, but no breakdown of net proceeds after fees is provided. The announcement details the company's organizational structure and strategic aspirations but does not disclose current revenue, cash position, or operational milestones. The only immediate, concrete use of funds is the settlement payment; other uses are broad and forward-looking. There is no evidence in this release of realized revenue, licensing deals, or near-term commercial progress resulting from this financing.

Analysis

The announcement is positive in tone, highlighting the successful closing of a $3.39 million private placement and the establishment of several business platforms. However, while the financing transaction itself is a realised fact, most of the claimed benefits—such as advancing the pharmaceutical and medical-device portfolio, generating licensing revenues, and supporting long-term development—are forward-looking and not yet realised. The use of proceeds is described in general terms, with only the $625,000 settlement payment being a near-term, concrete use; the remainder is allocated to broad, aspirational objectives. There is no disclosure of immediate revenue, profitability, or operational milestones resulting from this financing, and the stated benefits (licensing, royalties, commercialization) are long-term and uncertain. The language inflates the impact of the financing by linking it to broad strategic ambitions without evidence of near-term value creation. The capital intensity flag is triggered because the funds are significant relative to the company's likely scale, but the returns are projected and not immediate.

Risk flags

• ●Dilution risk is present due to the convertible nature of the notes, with conversion at 85% of the average VWAP after eight months. This could lead to significant share issuance if the stock price declines.
• ●The high 17.5% original issue discount and the $4,106,060 principal relative to $3.39 million in proceeds indicate expensive capital, which may signal limited access to lower-cost financing or investor concerns about risk.
• ●The majority of stated benefits are aspirational, with no immediate operational milestones or revenue impact disclosed. Execution risk remains high as the company must translate proceeds into tangible business progress.
• ●A substantial portion of proceeds ($625,000) is allocated to settle outstanding claims, reducing the amount available for productive investment and highlighting prior financial or legal pressures.

Bottom line

This financing provides ABVC with $3.39 million in gross proceeds, of which $625,000 is immediately committed to settling claims with Lind Global Fund II LP. The notes carry a high effective cost and introduce dilution risk due to their convertible structure at a discount to market. While the company outlines a multi-platform strategy and ambitious goals for licensing and business development, the announcement offers no evidence of near-term revenue or operational milestones. Most of the funds, aside from the settlement, are allocated to general purposes, with no detailed plan or measurable targets. Investors should focus on whether ABVC can convert this capital into concrete progress—such as signed deals, product advancement, or revenue—before the notes become convertible and before further dilution or refinancing becomes necessary. The key takeaway is that this is a costly, dilutive raise with immediate benefits limited to resolving past obligations, and long-term value creation remains unproven.

Announcement summary

(NASDAQ:ABVC) ABVC BioPharma, Inc. has closed a private placement of original issue discount senior convertible promissory notes (OID Notes) with institutional and other accredited investors, generating aggregate gross proceeds of approximately $3.39 million before placement agent fees and other offering expenses. The 17.5% OID Notes have an aggregate principal amount of $4,106,060 and mature on June 30, 2027. The notes are convertible, following the eight month anniversary of the issuance date, into shares of ABVC's common stock at a conversion price equal to 85% of the average of the three VWAPs for the three Trading Days immediately prior to the date of conversion, subject to the Floor Price and adjustment as provided in the agreement. Net proceeds from the offering are expected to be used for general working capital purposes, funding of subsidiaries, and a $625,000 settlement payment to Lind Global Fund II LP pursuant to a definitive release and settlement agreement. The $625,000 payment is expected to satisfy specified outstanding payment claims and support ABVC's ability to pursue broader financing and business development initiatives. The offering is expected to support ABVC's strategy of advancing its pharmaceutical and medical-device portfolio through strategic licensing, subsidiary development, and independent financing initiatives. ABVC has established dedicated business platforms including AiBtl BioPharma Inc. for CNS drug programs, OncoX BioPharma for oncology, ForSeeCon Eye for ophthalmic medical-device development and commercialization, and BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing services as well as AI Biotechnology Innovation Platform. Through these arrangements, ABVC seeks to advance development programs and create opportunities for licensing revenues, milestone payments, future royalties, and equity value. The company continues to evaluate potential strategic financing and capital-market opportunities for its affiliated businesses to support their long-term development and commercialization objectives. WallachBeth Capital, Inc. acted as the placement agent for the offering. Hunter Taubman Fischer & Li LLC acted as legal counsel to ABVC, and Sichenzia Ross Ference Carmel LLP acted as counsel to the placement agent. The notes and shares issuable upon conversion have not been registered under the Securities Act of 1933 or any state securities laws and may not be offered or sold in the United States or any state absent registration or an applicable exemption. Additional details regarding the notes and transaction will be available in ABVC's Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.

Disagree with this article?